Vivo Capital related stories
All articles and analysis
Revance Therapeutics Closes on $45MRevance Therapeutics Inc., a drug developer focused on dermatology and aesthetic medicine, has raised $45 million in new capital from Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation. Jonathan Tunnicliffe, a partner at NovaQuest, will join the Revance board as a result of the round. Revance closed a $25.62 million in Series D funding in late 2009.
- Job Moves: Kleiner Lures Huang from Vivo, CalPERS Gets Real, Founders Fund CFO Moves On, More
In this week's installment of Job Moves, we look at Kleiner Perkins' latest hire and the firm he left; a key private equity appointment for the nation's largest pension fund; a new fund for two former Insight GPs; a Brazilian expansion; and another very large pension fund that looks to be hiring. KP HIRES HUANG FROM VIVO Just a few days after Vivo Ventures announced the promotion of a partner to head its China operations, Kleiner Perkins Caufield & Byers announced /107715/james-huang-joins-kpcb-in-shanghai/ that it has hired former Vivo partner James Huang to advise on life science investments as a partner in its Shanghai office. Huang was a managing partner at Vivo and, previously,
- James Huang Joins KPCB in Shanghai
Kleiner Perkins Caufield & Byers has added James Huang as a partner in its Shanghai offices. Huang will advise on life science investments. Huang joins from life science-focused Vivo Ventures, where he was a managing partner. Earlier in his career, Huang was president of Anesiva, a biopharmaceutical company focused on pain management.
- Job Moves: Vivo Promotes Two, TA Goes to Hong Kong, Obama Appointee Joins Venrock, More
This is the first installment of a new feature that looks at who’s moving in, up (or out) in venture capital and private equity circles. In this week's column, Vivo Ventures promotes two doctors to managing partner, BlackRock makes the first three of an expected 20 new appointments, TA associates announces its first hire for a new Hong Kong office, Venrock adds a partner for health care IT, and a U.S. Venture Partners staffer joins a startup. VIVO ADDS TWO Vivo Ventures, a life science-focused venture firm based in Silicon Valley, announced promotions of two to managing partner this week, one of whom will be based in Palo Alto, Calif., and the other in China. The first is Chen Yu, who joined Vivo as a partner in 2007. Prior to Vivo, Yu was an early employee at aQuantive, which listed on Nasdaq in 2000 and ultimately was acquired for $6.5 billion by
- Vivo Ventures Promotes Two to MD
Vivo Ventures, a life science focused investment firm, has promoted Dr. Chen Yu and Dr. James Zhao to managing partners with the firm. Yu first joined Vivo in 2004 and has been a Partner since 2007. Zhao began working with the firm in late 2005. With his promotion to Managing Partner, he will now be heading Vivo’s China team. Palo Alto, Calif.-based Vivo Ventures has $750 million under management.
- Slideshow: Top Performing VC-backed Chinese IPOs
Qihoo 360 Technology Co. Ltd. hit the cover off the ball http://www.reuters.com/article/2011/03/30/us-qihoo-ipo-debut-idUSTRE72T3UB20110330 in its market debut yesterday. The VC-backed Chinese Internet company priced at $14.50 and soared more than 130% to $34 by the close of the day. As impressive as that was, Qihoo is not the top performing VC-backed Chinese IPO since the start of 2010, according to Thomson Reuters (publisher of this blog). See our slideshow to find out who's No. 1, and where Qihoo ranks in the top 10.
IPO Momentum Turns Into New Year WhimperOverall, the IPO market rebounded well in 2010
- NextWave Pharmaceuticals Secures $45 Million in Financing
NextWave Pharmaceuticals Inc. secured $45 million in a Series C financing, which was co-led by new investors Panorama Capital o Menlo Park, Calif., and Bay City Capital LLC of San Francisco, Calif. Kearny Venture Partners and current investors: Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures participated in the round. NextWave plans to use the capital to commercialize its NEXICLON™ XR product for the treatment of hypertension, to expand the CNS portfolio and to prepare for introduction of a novel extended-release liquid methylphenidate for Attention Deficit Hyperactivity Disorder.
- Week in deals, April 19, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- Sagent Pharma Raises $40 Million
Sagent Pharmaceuticals Inc., a Schaumburg, Ill.-based developer of injectible drugs, has raised $40 million in Series B funding. Zhejiang Hisun Pharmaceutical Co. Ltd.provided $10 million, while the remainder came from an undisclosed China-docused private equity fund. The firm previously raised over $110 million in VC funding from firms like Vivo Ventures.